X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adult (3) 3
aged (3) 3
carcinoma, non-small-cell lung - mortality (3) 3
chemotherapy (3) 3
female (3) 3
humans (3) 3
index medicus (3) 3
lung neoplasms - mortality (3) 3
male (3) 3
middle aged (3) 3
oncology (3) 3
aged, 80 and over (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
cancer (2) 2
cancer therapies (2) 2
carcinoma (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
care and treatment (2) 2
erlotinib (2) 2
hematology, oncology and palliative medicine (2) 2
lung cancer (2) 2
lung cancer, non-small cell (2) 2
lung neoplasms - drug therapy (2) 2
lung neoplasms - pathology (2) 2
neoplasm metastasis (2) 2
radiation therapy (2) 2
radiation-therapy (2) 2
survival (2) 2
adenocarcinoma - mortality (1) 1
adenocarcinoma - secondary (1) 1
adenocarcinoma - therapy (1) 1
analysis (1) 1
angiogenesis inhibitors - adverse effects (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antitumor-activity (1) 1
article (1) 1
bevacizumab (1) 1
body radiotherapy (1) 1
carboplatin - administration & dosage (1) 1
carcinoma, large cell - mortality (1) 1
carcinoma, large cell - secondary (1) 1
carcinoma, large cell - therapy (1) 1
carcinoma, non-small-cell lung - pathology (1) 1
carcinoma, non-small-cell lung - secondary (1) 1
carcinoma, non-small-cell lung - therapy (1) 1
carcinoma, squamous cell - mortality (1) 1
carcinoma, squamous cell - secondary (1) 1
carcinoma, squamous cell - therapy (1) 1
cetuximab (1) 1
chemoradiation (1) 1
chemoradiotherapy (1) 1
clinical-trials (1) 1
combination therapy (1) 1
combined modality therapy (1) 1
competing risk (1) 1
development and progression (1) 1
disease (1) 1
disease-free survival (1) 1
dosage and administration (1) 1
double-blind method (1) 1
efficacy (1) 1
endothelial growth-factor (1) 1
erlotinib hydrochloride (1) 1
follow-up studies (1) 1
histology (1) 1
ii-trial (1) 1
in-vivo (1) 1
indoles - adverse effects (1) 1
indoles - therapeutic use (1) 1
induction (1) 1
lung neoplasms - therapy (1) 1
management (1) 1
metastasis (1) 1
mutation (1) 1
neoplasm staging (1) 1
non-small-cell lung cancer (1) 1
original (1) 1
original articles (1) 1
paclitaxel - administration & dosage (1) 1
patients (1) 1
plus erlotinib (1) 1
prognosis (1) 1
protein kinase inhibitors - adverse effects (1) 1
protein kinase inhibitors - therapeutic use (1) 1
pyrroles - adverse effects (1) 1
pyrroles - therapeutic use (1) 1
quinazolines - adverse effects (1) 1
quinazolines - therapeutic use (1) 1
radiation (1) 1
radiotherapy (1) 1
radiotherapy dosage (1) 1
radiotherapy, conformal (1) 1
radiotherapy, image-guided (1) 1
receptor, epidermal growth factor - antagonists & inhibitors (1) 1
receptors, platelet-derived growth factor - antagonists & inhibitors (1) 1
receptors, vascular endothelial growth factor - antagonists & inhibitors (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 187 - 199
Summary Background We aimed to compare overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | COMPETING RISK | CLINICAL-TRIALS | THERAPY ONCOLOGY GROUP | CHEMORADIATION | INDUCTION | CARCINOMA | CHEMOTHERAPY | RADIATION-THERAPY | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Carcinoma, Large Cell - mortality | Radiotherapy, Image-Guided | Chemoradiotherapy | Carcinoma, Large Cell - secondary | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Non-Small-Cell Lung - secondary | Carcinoma, Squamous Cell - mortality | Aged, 80 and over | Adult | Female | Cetuximab | Paclitaxel - administration & dosage | Radiotherapy Dosage | Carboplatin - administration & dosage | Carcinoma, Squamous Cell - therapy | Survival Rate | Combined Modality Therapy | Lung Neoplasms - therapy | Carcinoma, Non-Small-Cell Lung - mortality | Adenocarcinoma - secondary | Carcinoma, Non-Small-Cell Lung - therapy | Adenocarcinoma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Radiotherapy, Conformal | Carcinoma, Squamous Cell - secondary | Aged | Neoplasm Staging | Carcinoma, Large Cell - therapy | Adenocarcinoma - mortality | Antimitotic agents | Care and treatment | Chemotherapy | Dosage and administration | Lung cancer, Non-small cell | Antineoplastic agents | Radiotherapy | Cancer | Index Medicus
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2013, Volume 24, Issue 9, pp. 2382 - 2389
Combined inhibition of vascular, platelet-derived, and epidermal growth factor receptor (EGFR) pathways may overcome refractoriness to single agents in... 
Non-small-cell lung cancer | Efficacy | Sunitinib | Safety | Erlotinib | Combination therapy | sunitinib | BEVACIZUMAB | erlotinib | ANTITUMOR-ACTIVITY | efficacy | SU11248 | CHEMOTHERAPY | TRIAL | ONCOLOGY | safety | IN-VIVO | combination therapy | TYROSINE KINASE INHIBITOR | PLUS ERLOTINIB | CARCINOMA | non-small-cell lung cancer | ENDOTHELIAL GROWTH-FACTOR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors | Double-Blind Method | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Survival | Disease-Free Survival | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Indoles - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Original
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.